Levetiracetam: The Profile of a Novel Anticonvulsant Drug—Part I: Preclinical Data

Tim De Smedt, Robrecht Raedt, Kristl Vonck, Paul Boon
{"title":"Levetiracetam: The Profile of a Novel Anticonvulsant Drug—Part I: Preclinical Data","authors":"Tim De Smedt,&nbsp;Robrecht Raedt,&nbsp;Kristl Vonck,&nbsp;Paul Boon","doi":"10.1111/j.1527-3458.2007.00004.x","DOIUrl":null,"url":null,"abstract":"<p>The objective of this article was to review and summarize the available reports on the preclinical profile of the novel anticonvulsant drug levetiracetam (LEV). Therefore, a careful search was conducted in the MEDLINE database and combined with guidelines from regulatory agencies, proceedings of professional scientific meetings, and information provided by the manufacturers. This article provides detailed information on the anticonvulsant effects of LEV in various animal models of epilepsy and on its pharmacology in laboratory animals. The mechanism of action of LEV is reviewed, with special regard to its recently discovered binding site, the synaptic vesicle protein 2A. In general, LEV is shown to be a safe, broad-spectrum anticonvulsant drug with highly beneficial pharmacokinetic properties and a distinct mechanism of action. The clinical studies with LEV will be discussed in the second part of this review article to be published subsequently.</p>","PeriodicalId":94307,"journal":{"name":"CNS drug reviews","volume":"13 1","pages":"43-56"},"PeriodicalIF":0.0000,"publicationDate":"2007-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1527-3458.2007.00004.x","citationCount":"74","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS drug reviews","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2007.00004.x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 74

Abstract

The objective of this article was to review and summarize the available reports on the preclinical profile of the novel anticonvulsant drug levetiracetam (LEV). Therefore, a careful search was conducted in the MEDLINE database and combined with guidelines from regulatory agencies, proceedings of professional scientific meetings, and information provided by the manufacturers. This article provides detailed information on the anticonvulsant effects of LEV in various animal models of epilepsy and on its pharmacology in laboratory animals. The mechanism of action of LEV is reviewed, with special regard to its recently discovered binding site, the synaptic vesicle protein 2A. In general, LEV is shown to be a safe, broad-spectrum anticonvulsant drug with highly beneficial pharmacokinetic properties and a distinct mechanism of action. The clinical studies with LEV will be discussed in the second part of this review article to be published subsequently.

左乙拉西坦:一种新型抗惊厥药物的概况——第一部分:临床前数据
本文的目的是回顾和总结有关新型抗惊厥药物左乙拉西坦(LEV)的临床前研究报告。因此,在MEDLINE数据库中进行了仔细的搜索,并结合了监管机构的指南、专业科学会议的会议记录和制造商提供的信息。本文详细介绍了LEV在各种癫痫动物模型中的抗惊厥作用及其在实验动物中的药理作用。本文综述了LEV的作用机制,特别关注其最近发现的结合位点突触囊泡蛋白2A。总的来说,LEV被证明是一种安全、广谱的抗惊厥药物,具有非常有益的药代动力学特性和独特的作用机制。LEV的临床研究将在随后发表的这篇综述文章的第二部分进行讨论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信